Taken together, our data suggests that the combined treatment with both Chk1 and GSK3-β inhibitors could be a novel effective therapy in triple negative cancers, but also possibly in other cancers in which inhibition of GSK3-β enhances Chk1 activation. The gene discussed is GSK3B; the disease is cancer.